Evidence map›Paper›PMID 28236061›Full record

ReviewPharmaceutical research2017

The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?

Mafalda M Dias, Michael J Sorich, Andrew Rowland, Michael D Wiese, Ross A McKinnon

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pharmaceutical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mafalda M DiasSchool of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.
Michael J SorichDepartment of Clinical Pharmacology, School of Medicine, Flinders University, Bedford Park, Australia.
Andrew RowlandDepartment of Clinical Pharmacology, School of Medicine, Flinders University, Bedford Park, Australia.
Michael D WieseSchool of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.
Ross A McKinnonFlinders Centre for Innovation in Cancer, School of Medicine, Flinders University, GPO Box 2100, Adelaide, SA, 5001, Australia. ross.mckinnon@flinders.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacogenetic testing aims to personalize drug therapy with a view to optimising drug efficacy and minimise toxicity. However, despite the potential benefits, pharmacogenetic testing is mostly confined to specialised medical areas, laboratories and centres. Widespread integration into routine clinical practice has been limited by a complex set of issues including regulatory and reimbursement frameworks, evidence of clinical utility and clinician perspectives, practices and education. Here we assess the current barriers to widespread clinical uptake and identify the key issue necessary to address to accelerate routine testing.

Indexed as

Biomarkers, PharmacologicalDose-Response Relationship, DrugHumansPharmacogeneticsPharmacogenomic TestingPrecision MedicineBiomarkers, Pharmacologicalbiomarkersclinical uptakediagnostic testspersonalized medicine

Identifiers

PMID28236061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.